“清肺排毒颗粒”治疗新型冠状病毒肺炎的临床疗效初探

Preliminary study on clinical efficacy of “Qingfei Paidu Granule” in treating coronavirus disease 2019

关键词:  新型冠状病毒肺炎  清肺排毒颗粒  临床研究

Key words:  coronavirus disease 2019  Qingfei Paidu Granule  clinical research

摘要:

[目的] 观察用清肺排毒颗粒治疗新型冠状病毒肺炎的初步临床疗效。[方法] 将确诊的76例新型冠状病毒肺炎患者纳入观察，使用清肺排毒颗粒进行治疗，5 d为1个疗程，治疗3个疗程后，比较患者服药前和服药后的中医证候积分的变化和实验室相关指标的改善情况，中医证候依据症状的轻重程度，采用评分的方法判定。[结果] 与治疗前相比，运用清肺排毒颗粒治疗5、10、15 d后，其证候总积分均明显下降（P<0.01）；主症、次症总积分均较治疗前明显下降，均具有统计学意义（P<0.01）。实验室检测显示，与治疗前相比，淋巴细胞百分率（LYMPH%）上升，丙氨酸氨基转移酶（ALT）、D-二聚体（D-Dimer）、C反应蛋白（CRP）和血沉（ESR）下降，逐渐恢复正常，差异具有统计学意义（P<0.01），核酸转阴及肺部计算机断层扫描（CT）好转率为92.10%。治疗5 d后，基本痊愈18例，显效26例，总有效率为57.89%；治疗10 d后，基本痊愈32例，显效27例，总有效率为77.63%；治疗15 d后，基本痊愈50例，显效17例，总有效率为88.16%。[结论] 清肺排毒颗粒能有效控制患者的临床症状以及改善实验室异常检测指标，能很好地用于新型冠状病毒肺炎的治疗，其临床效果显著，不良反应少，值得推广使用。

Abstract:

[Objective] To observe the preliminary clinical study on coronavirus disease 2019 (COVID-19) treated by Qingfei Paidu Granule (QFPDKL).[Methods] The 76 patients with COVID-19 were included in the observation and treated with QFPDKL,with 5 days as a course of treatment. After 3 courses of treatment,the changes of Traditional Chinese Medicine (TCM) syndrome scores and the improvement of laboratory related indicators were compared before and after treatment. TCM syndromes were judged by scoring method according to the severity of symptoms.[Results] Compared with before treatment,the total score of syndromes after treatment of QFPDKL for 5,10 and 15 days decreased significantly (P<0.01). The total scores of primary and secondary symptoms were significantly lower than those before treatment (P<0.01). Laboratory tests showed that compared with before treatment,lymphocyte percentage (LVMPH%) increased,alanine aminotransferase (ALT),D-Dimer,C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) decreased,and gradually returned to normal,the difference was statistically significant (P<0.01). The negative rate of nucleic acid and the improvement rate of lung computed tomography (CT) were 92.10%. After 5 days of treatment,18 cases were basically cured,26 cases were markedly effective,and the total effective rate was 57.89%. After 10 days of treatment,32 cases were basically cured,27 cases were markedly effective,and the total effective rate was 77.63%. After 15 days of treatment,50 cases were basically cured,17 cases were markedly effective and the total effective rate was 88.16%.[Conclusion] QFPDKL can effectively control patients' clinical symptoms and improve laboratory abnormal detection indicators,and can be well used in the treatment of COVID-19. Its clinical effect is remarkable,with few adverse reactions,and it is worth popularizing and using.